Research
The S&P 500's 49% Breadth: Why Index Strength Is Hiding a Pullback
The S&P 500 is holding near 7,650, but only 49% of members sit above their 200-day average. That is a breadth warning, not a bear-market call.
John Grey is a founding editor at Solomon Grey Capital, covering private credit, global macro, and institutional investment strategy across Asia and global markets.
Research
The S&P 500 is holding near 7,650, but only 49% of members sit above their 200-day average. That is a breadth warning, not a bear-market call.
Research
China's factories accelerated in August, but weak retail sales and falling investment show that production strength is outrunning household demand.
Research
Hong Kong followed the Fed to 4.25%, but the first stress signal is the HKD funding channel, not an immediate growth collapse.
Research
RBI's listing push is reviving Tata Sons shares, but an IPO may expose governance and valuation frictions before it unlocks value for investors.
Research
India's new 0.4% UPI merchant fee is less a consumer tax than a test of whether the world's largest instant-payments rail can fund its next phase without damaging adoption.
Research
Oil above $100 and a 5% Treasury yield are testing whether the Fed can contain inflation without making the long end of the curve even less forgiving.
Research
Oil above $100 is a fresh stress test for floating-rate borrowers, but the contrarian risk is margin compression and selective restructuring, not a systemic private-credit collapse.
Research
Lululemon's 81% slide looks cheap, but the harder question is whether the brand needs a multi-year reset before the old margin engine can return.
Research
The ECB's second hike of 2026 is a hedge against an energy shock, but softer core prices and modest growth forecasts make recession risk the cleaner contrarian trade.
Research
Copper is making records, but the signal is policy-driven scarcity: metal is moving into US warehouses while global surplus risk remains unresolved.
Research
China's reserves beat expectations in August as the yuan rose and the dollar fell. The signal is managed appreciation and export protection, not a dollar exit.
Research
Novartis's failed Lp(a) trial did not break biotech's rebound. It exposed the market's real test: capital is returning, but only to clinical proof and de-risked assets.